AIMS: To determine the co-prevalence of gout, diabetes and cardiovascular disease (CVD) in the entire Aotearoa New Zealand adult population to inform clinical practice. METHODS: Algorithms based on hospital admissions, outpatient visits, drug dispensing, laboratory test data and mortality for the Aotearoa New Zealand Health Tracker (ANZHT) population aged ≥20 years (n = 3,036,093) were used to estimate the prevalence of those identified with gout, diabetes and CVD in 2009. RESULTS: The crude prevalence in the adult ANZHT population of gout was 3.9%, of diabetes was 6.6%, and of CVD was 5.4%. For those identified with gout, 25.6% had diabetes and 22.7% had CVD. Both diabetes and CVD were more prevalent in those identified with gout, compared with those without gout (age-standardised rate (ASR) ratio 3.5 for diabetes and 2.7 for CVD, p for both <0.001). CONCLUSION: By applying algorithms based on hospital coding, community drug dispensing and laboratory test data sets, we have demonstrated a high co-prevalence of gout, diabetes and CVD in the adult population of Aotearoa New Zealand. Health service presentation with gout can be an important opportunity to assess risk and manage co-morbid disease. Prevention and management strategies are reinforcing for these metabolic conditions.
AIMS: To determine the co-prevalence of gout, diabetes and cardiovascular disease (CVD) in the entire Aotearoa New Zealand adult population to inform clinical practice. METHODS: Algorithms based on hospital admissions, outpatient visits, drug dispensing, laboratory test data and mortality for the Aotearoa New Zealand Health Tracker (ANZHT) population aged ≥20 years (n = 3,036,093) were used to estimate the prevalence of those identified with gout, diabetes and CVD in 2009. RESULTS: The crude prevalence in the adult ANZHT population of gout was 3.9%, of diabetes was 6.6%, and of CVD was 5.4%. For those identified with gout, 25.6% had diabetes and 22.7% had CVD. Both diabetes and CVD were more prevalent in those identified with gout, compared with those without gout (age-standardised rate (ASR) ratio 3.5 for diabetes and 2.7 for CVD, p for both <0.001). CONCLUSION: By applying algorithms based on hospital coding, community drug dispensing and laboratory test data sets, we have demonstrated a high co-prevalence of gout, diabetes and CVD in the adult population of Aotearoa New Zealand. Health service presentation with gout can be an important opportunity to assess risk and manage co-morbid disease. Prevention and management strategies are reinforcing for these metabolic conditions.
Authors: Iris J M Disveld; Sahel Zoakman; Tim L Th A Jansen; Gerard A Rongen; Laura B E Kienhorst; Hein J E M Janssens; Jaap Fransen; Matthijs Janssen Journal: Clin Rheumatol Date: 2019-03-30 Impact factor: 2.980
Authors: Mohanraj Krishnan; Tanya J Major; Ruth K Topless; Ofa Dewes; Lennex Yu; John M D Thompson; Lesley McCowan; Janak de Zoysa; Lisa K Stamp; Nicola Dalbeth; Jennie Harré Hindmarsh; Nuku Rapana; Ranjan Deka; Winston W H Eng; Daniel E Weeks; Ryan L Minster; Stephen T McGarvey; Satupa'itea Viali; Take Naseri; Muagututi'a Sefuiva Reupena; Phillip Wilcox; David Grattan; Peter R Shepherd; Andrew N Shelling; Rinki Murphy; Tony R Merriman Journal: Diabetologia Date: 2018-05-02 Impact factor: 10.122
Authors: Tahzeeb Fatima; Sara Altaf; Amanda Phipps-Green; Ruth Topless; Tanya J Flynn; Lisa K Stamp; Nicola Dalbeth; Tony R Merriman Journal: Rheumatol Int Date: 2015-09-26 Impact factor: 2.631
Authors: Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vazquez-Mellado; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor Journal: Arthritis Rheumatol Date: 2015-10 Impact factor: 10.995
Authors: Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor Journal: Ann Rheum Dis Date: 2015-10 Impact factor: 19.103
Authors: Murray Cadzow; Tony R Merriman; James Boocock; Nicola Dalbeth; Lisa K Stamp; Michael A Black; Peter M Visscher; Phillip L Wilcox Journal: BMC Med Genet Date: 2016-11-15 Impact factor: 2.103